Close Menu

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of olaparib (AstraZeneca/Merck's Lynparza) as a treatment for metastatic castration-resistant prostate cancer (CRPC) patients with BRCA1/2 mutations who have progressed on a hormonal agent.

Following CHMP's recommendation, the European Commission will review the opinion and decide whether to approve the regimen.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.